Impact of different dimethyl sulphoxide concentrations on cell recovery, viability and clonogenic potential of cryopreserved peripheral blood hematopoietic stem and progenitor cells

Smagur, Andrzej; Mitrus, Iwona; Giebel, Sebastian; Saduś-Wojciechowska, Maria; Najda, Jacek; Krużel, Tomasz; Czerw, Tomasz; Gliwinska, Joanna; Prokop, Magdalena; Głowala-Kosińska, Magdalena; Chwieduk, Agata; Hołowiecki, Jerzy

doi:10.1111/j.1423-0410.2012.01657.x

Cited by 29 publications

(22 citation statements)

References 36 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, in randomly selected 13 patients, 1 mL of the product was cryopreserved separately and further tested in a clonogenic assay, for the presence of burst-forming unit-erythroid (BFU-E), CFU-erythroid (CFU-E); CFU-granulocyte/macrophage (CFU-GM) and CFU-erythroid, granulocyte, macrophage, megakaryocyte (CFU-GEMM), as previously described. 28 …”

Section: Leukapheresesmentioning

confidence: 99%

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Giebel

Krużel

Czerw

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

The optimal protocol for mobilization of hematopoietic stem cells in patients with lymphoid malignancies has not been determined so far. We retrospectively analyzed the efficacy and safety of Ara-C at a dose of 1.6 g/m 2 compared with CY at a dose of 4.0 g/m 2 , both combined with filgrastim. Seventy and forty-five patients, respectively, were included, among whom 60% were defined as 'predicted poor mobilizers'. The use of Ara-C was associated with significantly higher peak number of circulating CD34þ cells compared with CY (Po0.0001). In the Ara-C group, 95% of patients with multiple myeloma (MM) collected at least 5 Â 10 6 CD34 þ cells/kg required for tandem transplantation, and 97% of lymphoma patients collected at least 2 Â 10 6 CD34 þ cells/kg, needed for a single autologous hematopoietic SCT (autoHSCT), which was achieved with a single leukapheresis in 91% of cases. Results for the CY group were significantly inferior (Po0.0001). No patient mobilized with Ara-C experienced febrile neutropenia, whereas 35% required platelet transfusions. Among patients who proceeded to autoHSCT, the time of both neutrophil and platelet recovery was significantly shorter for those mobilized with Ara-C than CY. We conclude that intermediate-dose Ara-C þ filgrastim is a very effective and relatively safe mobilization protocol for patients with lymphoid malignancies.Bone Marrow Transplantation (2013) 48, 915-921;

show abstract

Section: Leukapheresesmentioning

confidence: 99%

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Giebel

Krużel

Czerw

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…A 2013 preclinical study, followed by two clinical trials, looked at three DMSO concentrations (10, 7.5, and 5%) for cryopreservation of HSCs [25-27]. Preclinical results showed a decrease in nucleated cell recovery for concentrations of DMSO below 10%, but found the highest number of colonies formed from cells frozen in 7.5% DMSO [25].…”

Section: New Cryoprotectantsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

“…Differences regard many factors that have been demonstrated to affect the quality of the hematopoietic stem/progenitor cells after thawing. These are as follows: cell storage conditions before cryopreservation [23][24][25][26], cooling rate of cells (freezing curve) [7,18,26,27], temperature and speed of adding cryoprotective mixture [24][25][26] and final DMSO and cell concentration [21,[28][29][30][31][32][33][34][35][36]. In particular, in our previous studies, we demonstrated that cryopreservation with 7Á5% DMSO was associated with higher clonogenic potential and faster post-transplant engraftment compared with 10% DMSO [21,29].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Impact of different dimethyl sulphoxide concentrations on cell recovery, viability and clonogenic potential of cryopreserved peripheral blood hematopoietic stem and progenitor cells

Abstract: Reduction in DMSO concentration from 10% to 7·5% may have favourable impact on hematopoietic recovery after autologous transplantation. The findings require confirmation in a clinical setting.

Cited by 29 publications

References 36 publications

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation

Contact Info

Product

Resources

About